AVXL ALZHEIMERS INTERIM PEEK?: Interestingly and predictably various BPs are restarting the Amyloid clearing drugs in clinical trials based on the FDA awarding Biogen approval of Aduhelm based on clearing Amyloid. Apparently one can not educate the ignorant FDA on science matters and there is no cure for unmitigated greed.
Best way to kill this off [if possible] would be an interim analysis of those probably 50% of patients already done with the Alzheimers trial.
Got to have the alternative being considered in the FDA and TGA if we are going to nip the amyloid tree in the bud. Biostock was 100% correct on this.
Most likely the vast majority of those who already completed the trial are Aussies, so a readout and push for TGA approval is the way to go, plus they are already well familiar with Anavex.
Waiting another year might insure BP money and treachery wins over Anavex science.
News 
Market Data 
Discover 
